Get Usa - Foxfireglobal - Sirtex

Overall, the lifetime risk of developing colorectal cancer is about 1 in 23 for men and 1 in 25 for women. However, each person's risk might be higher or lower than this, depending on their risk factors for colorectal cancer.

Colon cancer is typically slow-growing, starting as a benign polyp that eventually becomes malignant. This process may occur over many years without producing any symptoms. Once colon cancer has developed, it may still be years before it is detected.

Cancer of the colon is a highly treatable and often curable disease when localized to the bowel. Surgery is the primary form of treatment and results in cure in approximately 50% of patients. However, recurrence following surgery is a major problem and is often the ultimate cause of death.

FOXFIRE protocol: an open-label, randomised, phase III trial of 5-, and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer. BMC Cancer.

If the cancer has spread to surrounding tissues or organs and/or the regional lymph nodes, the 5-year relative survival rate is 72%. If colon cancer has spread to distant parts of the body, the 5-year relative survival rate is 13%. For rectal cancer, the overall 5-year relative survival rate for people is 68%.

Colorectal cancer is the fourth most common cancer in the U.S. among men and women combined. Each year, about 150,000 Americans are diagnosed with colorectal cancer. More than 50,000 people will die from colorectal cancer this year. One in 24 people will be diagnosed with colorectal cancer in their lifetime.